Providence Therapeutics Holdings Inc.
$6,400,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2020-2021
- Agreement period
- September 1, 2020 – July 30, 2021
- Reference
- nrc-cnrc:172-2020-2021-Q3-957288
Published purpose
Providence Therapeutics, Canada’s leading mRNA vaccine manufacture, is manufacturing an mRNA vaccine against COVID-19. The company is in the R&D phases to demonstrate the preclinical and clinical efficacy of PTX-COVID19-B.
In plain English AI-generated
Funding supports Providence Therapeutics in developing and manufacturing an mRNA COVID-19 vaccine, including preclinical and clinical research.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.